Estrogen receptor β promoter methylation: a potential indicator of malignant changes in breast cancer

Gao, Lei; Qi, Xiaolong; Hu, Kaiwen; Zhu, Rencheng; Xu, Wei; Sun, Shipeng; Zhang, Lixin; Yang, Ximing J.; Bai, Hua; Liu, Guijian

doi:10.5114/aoms.2016.57588

Cited by 9 publications

(6 citation statements)

References 26 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering methylation of a gene promoter can reduce the expression of that gene and may contribute to the development of cancer,14, 15, 16 the methylation analysis of LAMA3 revealed the presence of a large number of CpG islands in the LAMA3 promoter (Figure 5A). Furthermore, methylation-specific PCR (MSP) was used to study the methylation status of LAMA3 in the normal cell line BEAS-2B and the lung adenocarcinoma cell line H1650.…”

Section: Resultsmentioning

confidence: 99%

Long Non-coding RNA LINC00628 Interacts Epigenetically with the LAMA3 Promoter and Contributes to Lung Adenocarcinoma

Zheng

Zhang

et al. 2019

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) have emerged as key regulators of cellular progress in lung adenocarcinoma. In this study, to identify cancer-related lncRNAs and genes, we screened for those lncRNAs that were differentially expressed in lung adenocarcinoma, which revealed LINC00628 overexpression and low expression of laminin subunit alpha 3 (LAMA3). This was further validated in the cancerous tissues from patients diagnosed with lung adenocarcinoma. Thereafter, we explored the functional relevance of LINC00628 and LAMA3 in lung adenocarcinoma by analyzing the recruitment of DNA methyltransferase (DNMT) and the cellular processes of lung adenocarcinoma cells following treatments that induced LINC00628 overexpression or LINC00628 silencing or with 5-azacytidine (5-Aza, a DNMT inhibitor). The results showed that LINC00628 silencing decreased cell proliferation, migration, and invasion as well as the drug resistance of lung adenocarcinoma cells to vincristine (VCR). The results were opposite in the cells with LAMA3 demethylation induced by 5-Aza treatment. Further research indicated that LINC00628 recruited DNMT1, DNMT3A, and DNMT3B to promote the methylation of LAMA3 promoter, thereby decreasing its expression. Moreover, an in vivo experiment was performed in nude mice to assess the tumor growth ability and drug resistance of human lung adenocarcinoma cells. It was observed that LINC00628 silencing or 5-Aza treatment inhibited the in vivo tumor growth ability of the human lung adenocarcinoma cells and reduced their resistance to VCR. Altogether, our results provide evidence of a mechanism by which LINC00628 silencing exerts an inhibitory role in lung adenocarcinoma by modulating the DNA methylation of LAMA3, indicative of a novel molecular target for treatment of lung adenocarcinoma patients showing resistance to VCR.

show abstract

Section: Resultsmentioning

confidence: 99%

Long Non-coding RNA LINC00628 Interacts Epigenetically with the LAMA3 Promoter and Contributes to Lung Adenocarcinoma

Zheng

Zhang

et al. 2019

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

show abstract

“…Comparing breast cancer tissues and adjacent normal tissues, Gao et al found a significant difference in methylation level and mRNA expression. There was also a significantly lower expression of mRNA in pre-cancerous tissue compared to tissue in a more progressive breast cancer state [154]. Some researchers and our group came to the conclusion that the hypermethylation of the ESR2 gene ON promoter was associated with more progressed disease [67,68].…”

Section: Erβ In Breast Cancer and Its Metastasesmentioning

confidence: 90%

Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases

Božović

Mandušić

Todorović

et al. 2021

IJMS

View full text Add to dashboard Cite

The discovery of the Estrogen Receptor Beta (ERβ) in 1996 opened new perspectives in the diagnostics and therapy of different types of cancer. Here, we present a review of the present research knowledge about its role in endocrine-related cancers: breast, prostate, and thyroid, and colorectal cancers. We also discuss the reasons for the controversy of its role in carcinogenesis and why it is still not in use as a biomarker in clinical practice. Given that the diagnostics and therapy would benefit from the introduction of new biomarkers, we suggest ways to overcome the contradictions in elucidating the role of ERβ.

show abstract

“…Many studies have confirmed that ERβ gene silencing mediated by DNA methylation is an important mechanism in breast cancer [109]. Compared to those of adjacent normal tissues, the methylation level of breast cancer is significantly higher, which may be the reason for the decreased ERβ gene expression [110]. According to Mirza et al, patients with concurrent hypermethylation of ERβ and retinoic acid receptor β2 (RARβ2) showed a significantly shorter median OS [47].…”

Section: Dna Methylationmentioning

confidence: 99%

The role of estrogen receptor beta in breast cancer

Zhou

Liu

2020

Biomark Res

View full text Add to dashboard Cite

Breast cancer, a malignant tumor originating from mammary epithelial tissue, is the most common cancer among women worldwide. Challenges facing the diagnosis and treatment of breast cancer necessitate the search for new mechanisms and drugs to improve outcomes. Estrogen receptor (ER) is considered to be important for determining the diagnosis and treatment strategy. The discovery of the second estrogen receptor, ERβ, provides an opportunity to understand estrogen action. The emergence of ERβ can be traced back to 1996. Over the past 20 years, an increasing body of evidence has implicated the vital effect of ERβ in breast cancer. Although there is controversy among scholars, ERβ is generally thought to have antiproliferative effects in disease progression. This review summarizes available evidence regarding the involvement of ERβ in the clinical treatment and prognosis of breast cancer and describes signaling pathways associated with ERβ. We hope to highlight the potential of ERβ as a therapeutic target.

show abstract

Estrogen receptor β promoter methylation: a potential indicator of malignant changes in breast cancer

Cited by 9 publications

References 26 publications

Long Non-coding RNA LINC00628 Interacts Epigenetically with the LAMA3 Promoter and Contributes to Lung Adenocarcinoma

Long Non-coding RNA LINC00628 Interacts Epigenetically with the LAMA3 Promoter and Contributes to Lung Adenocarcinoma

Estrogen Receptor Beta: The Promising Biomarker and Potential Target in Metastases

The role of estrogen receptor beta in breast cancer

Contact Info

Product

Resources

About